Numerous examples have been found by high-throughput approaches, including microarray and next-generation sequencing analyses—for instance, TMPRSS2-ETS [24, 25] and D2HGDH-GAL3ST2 [26] in prostate cancer, LHX6-NDUFA8 and SLC2A11-MIF in cervical cancer [27], GOLM1-MAK10 in esophageal squamous cell carcinoma (ESCC) [28], EML4-ALK in non-small cell lung cancer (NSCLC) [29], CHFR-GOLGA3 in bladder cancer [30], RRM2-C2orf48 in colorectal cancer (CRC) [31], and ASTN2-PAPPAas in esophageal cancer [32]. This evidence concerns the gene LHX6 and urinary bladder cancer.